Dr. Brotzu has a patent on the technology that was approved in late 2013. Another one was approved in early 2013. Yet another one was approved in 2015, and that one outlines the use of dihomo-gamma-linolenic acid (DGLA).
The patents are filed under the auspices of Fidia Farmaceutici S.P.A., a reputable pharmacy based in Italy.
Dr. Brotzu also has a number of other patents to his name, related to his work as a vascular surgeon. In fact his experience in circulatory disorders and diabetes were initially what made him discover the benefits of treating hair loss with PGE1. Diabetics and people with circulatory disorders tend to see a loss of leg hair.
The good doctor has given some intelligent interviews that sound sincere and accurate based on my cursory glance. See here, here, and here. Italian to English translation needed for all those interviews.
The product will also include equol, which supposedly blocks the synthesis of dihydrotestosterone from testosterone. The patent states “a plant estrogen selected from equol, preferably S-equol, genistein, daidzein, glycitein.“
Here is the doctor’s important explanation of the necessity of using DGLA, per one of the interviews (note that liposomal delivery is required for skin penetration):